血液恶性肿瘤患者中不对称和对称二甲基精氨酸与死亡率：一项前瞻性研究。
Asymmetric and symmetric dimethylarginines and mortality in patients with hematological malignancies-A prospective study.
机构信息
Department of Angiology, Wroclaw Medical University, Wroclaw, Poland.
Department of Biochemistry, Wroclaw Medical University, Wroclaw, Poland.
出版信息
PLoS One. 2018 May 22;13(5):e0197148. doi: 10.1371/journal.pone.0197148. eCollection 2018.
The study was designed to determine the associations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginines plasma concentrations with all-cause mortality in patients with hematological malignancies. 33 patients with acute myeloid leukemia (AML), 31 patients with non-Hodgkin's lymphoma (nHL), 32 patients with chronic lymphocytic leukemia (CLL) and 48 patients without malignancy were enrolled into the study. Each patient was followed until death or for at least 14.5 months (range: 14.5-53). Median ADMA and SDMA were significantly elevated in AML, nHL and CLL compared to controls (ADMA: 1.36, 1.24, 1.03, 0.55 μmol/l respectively, p<0.0001; SDMA: 0.86, 0.76, 0.71, 0.52 μmol/l respectively, p<0.0001). High ADMA and SDMA were associated with increased risk for all-cause mortality in CLL group (Hazard ratio (HR) for ADMA: 3.05, 95% CI:1.58-5.88, p = 0.001; HR for SDMA: 4.71, 95% CI:1.91-11.58, p = 0.001). Our study suggests that ADMA and SDMA could be novel prognostic factors for all-cause mortality in CLL patients.
这项研究旨在确定不对称二甲基精氨酸（ADMA）和对称二甲基精氨酸（SDMA）血浆浓度与血液系统恶性肿瘤患者全因死亡率的相关性。研究纳入了 33 例急性髓系白血病（AML）患者、31 例非霍奇金淋巴瘤（nHL）患者、32 例慢性淋巴细胞白血病（CLL）患者和 48 例无恶性肿瘤患者。每位患者均随访至死亡或至少 14.5 个月（范围：14.5-53）。与对照组相比，AML、nHL 和 CLL 患者的 ADMA 和 SDMA 中位数明显升高（ADMA：分别为 1.36、1.24、1.03 和 0.55 μmol/l，p<0.0001；SDMA：分别为 0.86、0.76、0.71 和 0.52 μmol/l，p<0.0001）。高 ADMA 和 SDMA 与 CLL 组全因死亡率增加相关（ADMA 的风险比（HR）为 3.05，95%CI：1.58-5.88，p = 0.001；SDMA 的 HR 为 4.71，95%CI：1.91-11.58，p = 0.001）。我们的研究表明，ADMA 和 SDMA 可能是 CLL 患者全因死亡率的新的预后因素。
Zotero 插件